<DOC>
	<DOC>NCT01681134</DOC>
	<brief_summary>The purpose of the study is to evaluate the drug profiles (pharmacokinetics) and effects (pharmacodynamics) of Advagraf® and Prograf® on the kidneys.</brief_summary>
	<brief_title>A Comparison of the Effects of Extended Release Tacrolimus (Advagraf®) vs. Immediate Release Tacrolimus (Prograf®) on Kidney Function in Healthy Male Volunteers</brief_title>
	<detailed_description>This is a 2 Period study. In Period 1, subjects will be assigned randomly to receive Advagraf® or Prograf® administered once or twice daily, respectively, for a period of 10 days. In Period 2, subjects will be converted from Advagraf® to Prograf® or from Prograf® to Advagraf® for 10 additional days of dosing. Dose adjustments will be made based on the monitoring of drug levels in blood.</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Caucasian No previous/current history of infection, cerebrovascular, neurological, cardiovascular, endocrine, pulmonary, immunologic or metabolic disease or significant systemic disease, glucose intolerance, gout or hematological disorder Normal 12lead Electrocardiogram (ECG) Systolic blood pressure &lt;140 mm Hg and diastolic blood pressure &lt;90 mm Hg Nonsmoker within 3 months prior to screening Willing to abstain from alcohol during the study Positive screen for illicit drug or alcohol consumption Subject has hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or history of cancer (excluding completely excised squamous or basal cell carcinoma) Positive tuberculin skin test or known history of tuberculosis infection Known history of serious head injuries, seizures or eating disorders Body Mass Index &lt;18.0 or &gt;30.0 History of renal dysfunction, clinically significant creatinine or clinically significant abnormal liver function tests, hemoglobin &lt;130 g/L Plasma donation ≥ 500 mL within 7 days prior to first dose of study drug, donation or whole blood loss 50499 mL within 30 days or ≥ 499 mL within 56 days prior to first dose of study drug. Drug or alcohol abuse within 1 year prior to study entry Steroid injections within 12 weeks prior to first dose of study drug Live vaccine within 7 days prior to first dose of study drug</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>tacrolimus</keyword>
	<keyword>Advagraf®</keyword>
	<keyword>Prograf®</keyword>
	<keyword>Glomerular Filtration Rate</keyword>
	<keyword>Effective Renal Plasma Flow</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>